JP7476216B2 - ファルネソイドx受容体モジュレータとしての置換二環式化合物 - Google Patents

ファルネソイドx受容体モジュレータとしての置換二環式化合物 Download PDF

Info

Publication number
JP7476216B2
JP7476216B2 JP2021547528A JP2021547528A JP7476216B2 JP 7476216 B2 JP7476216 B2 JP 7476216B2 JP 2021547528 A JP2021547528 A JP 2021547528A JP 2021547528 A JP2021547528 A JP 2021547528A JP 7476216 B2 JP7476216 B2 JP 7476216B2
Authority
JP
Japan
Prior art keywords
alkyl
bicyclo
phenyl
methyl
oxadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519770A (ja
JP2022519770A5 (cg-RX-API-DMAC7.html
Inventor
エイ ワッカー,ディーン
ジェタナンド ナラ,スシール
チェルク,スリニバス
サルクナム,カンダサミー
アリ ジャイプリ,フィロツ
タンガベル,スーダマニ
ナラヤン,リシケシュ
レディ バンドレディ,スッバ
ジョギ,スリニバス
カルヤン カティ,パバン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2022519770A publication Critical patent/JP2022519770A/ja
Publication of JP2022519770A5 publication Critical patent/JP2022519770A5/ja
Application granted granted Critical
Publication of JP7476216B2 publication Critical patent/JP7476216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
JP2021547528A 2019-02-15 2020-02-14 ファルネソイドx受容体モジュレータとしての置換二環式化合物 Active JP7476216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806066P 2019-02-15 2019-02-15
US62/806,066 2019-02-15
PCT/US2020/018203 WO2020168143A1 (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators

Publications (3)

Publication Number Publication Date
JP2022519770A JP2022519770A (ja) 2022-03-24
JP2022519770A5 JP2022519770A5 (cg-RX-API-DMAC7.html) 2022-12-22
JP7476216B2 true JP7476216B2 (ja) 2024-04-30

Family

ID=69811921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547528A Active JP7476216B2 (ja) 2019-02-15 2020-02-14 ファルネソイドx受容体モジュレータとしての置換二環式化合物

Country Status (18)

Country Link
US (2) US11254663B2 (cg-RX-API-DMAC7.html)
EP (1) EP3924336A1 (cg-RX-API-DMAC7.html)
JP (1) JP7476216B2 (cg-RX-API-DMAC7.html)
KR (1) KR102927636B1 (cg-RX-API-DMAC7.html)
CN (1) CN113710656B (cg-RX-API-DMAC7.html)
AR (1) AR118050A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020223316A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015689A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129492A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002093A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021010611A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192276A1 (cg-RX-API-DMAC7.html)
IL (1) IL285246B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021009694A (cg-RX-API-DMAC7.html)
PE (1) PE20211701A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108792WA (cg-RX-API-DMAC7.html)
TW (1) TWI808305B (cg-RX-API-DMAC7.html)
WO (1) WO2020168143A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7465883B2 (ja) * 2019-02-15 2024-04-11 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレータとしての置換二環式化合物
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
CA3201686A1 (en) 2021-01-14 2022-07-21 Fabiola Terzi Method for treating chronic kidney diseases
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
TW202308629A (zh) 2021-04-28 2023-03-01 法商Enyo製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
IL316542A (en) * 2022-04-29 2024-12-01 Jiangsu Yahong Meditech Co Ltd Pyrimidine compound, method for its preparation, and pharmaceutical use thereof
CN115057996B (zh) * 2022-06-24 2023-06-02 河南工程学院 4CzIPN型多孔有机聚合物的制备方法及其应用
JP2026524534A (ja) * 2023-07-13 2026-07-22 ウエヌイグレックオ・ファーマ 4-クロロ-5-[4-(2,6-ジクロロフェニル)スルホニルピペラジン-1-イル]-1-ベンゾフラン-2-カルボン酸のl-リジン塩及びそのさまざまな形態
EP4743449A1 (en) * 2023-07-13 2026-05-20 ENYO Pharma L-ARGININE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREIN

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170166A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170182A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2020160010A1 (en) 2019-01-28 2020-08-06 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis
JP2022519771A (ja) 2019-02-15 2022-03-24 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレータとして有用な置換アミド化合物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013101A1 (fr) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
WO1998017276A1 (en) 1996-10-25 1998-04-30 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
JP4383177B2 (ja) 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション hPPAR活性化剤
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
EP1551813A4 (en) 2002-10-10 2007-07-11 Smithkline Beecham Corp CHEMICAL COMPOUNDS
AU2003290796A1 (en) 2002-11-14 2004-06-15 The Scripps Research Institute Non-steroidal fxr agonists
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
AU2006235115C1 (en) 2005-04-08 2013-02-28 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
ATE526318T1 (de) 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
WO2008011130A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
WO2008094556A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
BRPI0812851A2 (pt) 2007-07-02 2014-09-30 Glaxosmithkline Llc Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010058318A1 (en) 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
AU2010272523A1 (en) 2009-07-15 2012-02-02 Merck Serono S.A. Tetrazole derivatives
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2012087520A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
JP6099753B2 (ja) 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド スピロ環化合物、その組成物及びその医薬応用
WO2014071247A1 (en) 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors
TW201437200A (zh) 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
EP3019196B1 (en) 2013-07-09 2018-06-06 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
WO2015172747A1 (en) 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
JP6564406B2 (ja) 2014-06-19 2019-08-21 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カゼインキナーゼ1デルタ/イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
US10208573B2 (en) 2014-09-10 2019-02-19 Halliburton Energy Services, Inc. Perforating gun with integrated retaining system
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
SG11201704340VA (en) 2014-12-18 2017-07-28 Novartis Ag Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
CN106146483A (zh) 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
EP3350165B1 (en) 2015-09-16 2023-07-26 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN108602811B (zh) 2016-02-01 2021-11-16 轩竹生物科技有限公司 Fxr受体激动剂
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
SI3419624T1 (sl) 2016-02-22 2021-05-31 Novartis Ag Postopki za uporabo agonistov FXR
LT3419625T (lt) 2016-02-22 2021-07-26 Novartis Ag Fxr agonistų panaudojimo būdai
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途
WO2018170173A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20200131132A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170165A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP7588289B2 (ja) 2019-02-15 2024-11-22 ニュートリエン・エージー・ソリューションズ・(カナダ)・インコーポレイテッド 植物の健康を増進するプロトポルフィリンix誘導体及びその使用
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170166A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170182A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2020160010A1 (en) 2019-01-28 2020-08-06 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis
JP2022519771A (ja) 2019-02-15 2022-03-24 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレータとして有用な置換アミド化合物

Also Published As

Publication number Publication date
JP2022519770A (ja) 2022-03-24
SG11202108792WA (en) 2021-09-29
CN113710656B (zh) 2026-04-17
AR118050A1 (es) 2021-09-15
KR20210127220A (ko) 2021-10-21
TWI808305B (zh) 2023-07-11
US11254663B2 (en) 2022-02-22
US20210261535A1 (en) 2021-08-26
IL285246A (en) 2021-09-30
BR112021015689A2 (pt) 2021-10-26
EP3924336A1 (en) 2021-12-22
CL2021002093A1 (es) 2022-02-18
CN113710656A (zh) 2021-11-26
IL285246B2 (en) 2024-09-01
CA3129492A1 (en) 2020-08-20
PE20211701A1 (es) 2021-09-01
AU2020223316A1 (en) 2021-10-07
CO2021010611A2 (es) 2021-08-30
KR102927636B1 (ko) 2026-02-12
WO2020168143A1 (en) 2020-08-20
TW202045498A (zh) 2020-12-16
US11713312B2 (en) 2023-08-01
IL285246B1 (en) 2024-05-01
US20220135550A1 (en) 2022-05-05
MX2021009694A (es) 2021-09-10
EA202192276A1 (ru) 2021-11-26

Similar Documents

Publication Publication Date Title
US11713312B2 (en) Substituted bicyclic compounds as farnesoid X receptor modulators
WO2019089670A1 (en) Alkene compounds as farnesoid x receptor modulators
WO2020168148A1 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
JP2017523223A (ja) β−セクレターゼ阻害剤としてのシクロプロピル縮合チアジン−2−アミン化合物及び使用方法
SG11202108794RA (en) Substituted amide compounds useful as farnesoid x receptor modulators
US20130281463A1 (en) Diaza-spiro[5.5]undecanes useful as orexin receptor antagonists
JP7465883B2 (ja) ファルネソイドx受容体モジュレータとしての置換二環式化合物
JP7449300B2 (ja) ファルネソイドx受容体モジュレータとして有用な置換アミド化合物
EA047337B1 (ru) Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240417

R150 Certificate of patent or registration of utility model

Ref document number: 7476216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150